WNT5A and neoplasm: WNT ligands (e.g., WNT2, WNT5A) from tumor cells and cancer-associated fibroblasts (CAFs) in the TME activate the Wnt pathway through the proliferation of CSCs and resurrection of dormant CSCs, causing treatment resistance and cancer recurrence (63).